**Supplementary Table 1.** One-way sensitivity analysis of DS averted by three strategies

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **uptake rate of NIPT** | 20% | 40% | 60% | 80% | 100% |
| CMSS strategy DS averted | 3.02 |
| Contingent screening strategy DS averted | 7.53 |
| Universal screening strategy DS averted | 2.85 | 5.69 | 8.54 | 11.39 | 14.24 |
| **uptake rate of CMSS** | 20% | 40% | 60% | 80% | 100% |
| CMSS strategy DS averted | 0.9 | 1.8 | 2.7 | 3.6 | 4.5 |
| Contingent screening strategy DS averted | 2.25 | 4.5 | 6.75 | 9 | 11.25 |
| Universal screening strategy DS averted | 9.97 |
| **incidence of DS**  | 0.86‰ | 1.26‰ | 1.66‰ | 2.06‰ | 2.4‰ |
| CMSS strategy DS averted | 1.73 | 2.53 | 3.34 | 4.14 | 4.83 |
| Contingent screening strategy DS averted | 4.32 | 6.33 | 8.34 | 10.35 | 12.06 |
| Universal screening strategy DS averted | 5.71 | 8.37 | 11.03 | 13.69 | 15.94 |

DS, Down syndrome; CMSS, conventional maternal serum screening; NIPT, non-invasive prenatal testing;